Stem Cell Theranostics;Capella Biosciences, Inc.; Inc.;Stem Cell Theranostics, Inc.
发明人:
Armstrong, Christopher G.,Kim, Kevin J.,Pham, Lisa Maria Lucia,Park, Eunhye,Zhong, Zhong,Huang, Guanyi,Wu, Joseph C.,Elmer, Sidney Paul,Visuthikraisee, Viwat,Cadag, Eithon Michael G.,Freeman, Thomas B
申请号：
AU2017214668
公开号：
AU2017214668A1
申请日:
2017.02.03
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3',4',5'-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
